Cargando…
Is tenofovir monotherapy a sufficient defense line against multi-drug resistant hepatitis B virus?
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
The Korean Association for the Study of the Liver
2017
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5628003/ https://www.ncbi.nlm.nih.gov/pubmed/28942622 http://dx.doi.org/10.3350/cmh.2017.0045 |
| _version_ | 1783268813077217280 |
|---|---|
| author | Lee, Yun Bin Lee, Jeong-Hoon |
| author_facet | Lee, Yun Bin Lee, Jeong-Hoon |
| author_sort | Lee, Yun Bin |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-5628003 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2017 |
| publisher | The Korean Association for the Study of the Liver |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-56280032017-10-06 Is tenofovir monotherapy a sufficient defense line against multi-drug resistant hepatitis B virus? Lee, Yun Bin Lee, Jeong-Hoon Clin Mol Hepatol Editorial The Korean Association for the Study of the Liver 2017-09 2017-09-19 /pmc/articles/PMC5628003/ /pubmed/28942622 http://dx.doi.org/10.3350/cmh.2017.0045 Text en Copyright © 2017 by The Korean Association for the Study of the Liver This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
| spellingShingle | Editorial Lee, Yun Bin Lee, Jeong-Hoon Is tenofovir monotherapy a sufficient defense line against multi-drug resistant hepatitis B virus? |
| title | Is tenofovir monotherapy a sufficient defense line against multi-drug resistant hepatitis B virus? |
| title_full | Is tenofovir monotherapy a sufficient defense line against multi-drug resistant hepatitis B virus? |
| title_fullStr | Is tenofovir monotherapy a sufficient defense line against multi-drug resistant hepatitis B virus? |
| title_full_unstemmed | Is tenofovir monotherapy a sufficient defense line against multi-drug resistant hepatitis B virus? |
| title_short | Is tenofovir monotherapy a sufficient defense line against multi-drug resistant hepatitis B virus? |
| title_sort | is tenofovir monotherapy a sufficient defense line against multi-drug resistant hepatitis b virus? |
| topic | Editorial |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5628003/ https://www.ncbi.nlm.nih.gov/pubmed/28942622 http://dx.doi.org/10.3350/cmh.2017.0045 |
| work_keys_str_mv | AT leeyunbin istenofovirmonotherapyasufficientdefenselineagainstmultidrugresistanthepatitisbvirus AT leejeonghoon istenofovirmonotherapyasufficientdefenselineagainstmultidrugresistanthepatitisbvirus |